Obesity Clinical Trial
— EIM+Official title:
Feasibility and Acceptability of Incorporating Fitbit Smartwatches Into a Health System Referral Based Exercise is Medicine Program in Older Individuals (EIM+)
The effects of exercise on prevention and improved control of chronic diseases, reduced mortality, and improved quality of life are well established. Exercise has been shown to prevent heart disease, stroke, type 2 diabetes, depression, and certain types of cancers. In addition to prevention, physical activity is included in the standard or care for many chronic diseases and used in treatment. For example, the American Diabetes Association has identified positive health behaviors like physical activity as foundational in the treatment and management of disease and improving overall quality of life. The Ohio State University Wexner Medical Center Exercise is Medicine Program (EIM) is a physician referral program that aims to increase physical activity to prevent and reduce complications from chronic disease. The integration of technology among a 65+ population of EIM participants provides a novel approach to improving individual's health. Thus, our study aims to provide EIM participants aged 65+ with smartwatches in the hopes of increasing their overall physical activity levels.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | September 30, 2025 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Age 65+ - No healthcare provider-imposed limitations on physical activity - English-speaking Exclusion Criteria: - Symptoms suggestive of coronary artery disease (CAD) or congestive heart failure (CHF) (i.e. chest pain, dizziness, syncope, excessive dyspnea on exertion) - Myocardial infarction within the last 12 months - Revascularization within the last 12 months - Stroke/transient ischemic attack (TIA) within the past 12 months - Unstable angina - Congestive heart failure (New York Heart Association (NYHA) Class II, III or IV) - Ventricular arrhythmia - Clinically significant cardiac valve disease - Blood pressure >160/100 mmHg - Uncontrolled seizure disorder - Major surgery within the past three months - Severe or frequent hypoglycemia - Inability to independently manage blood glucose during activity - Severe autonomic or peripheral neuropathy - Active foot ulcers - Unstable retinopathy. |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of EIM+ | The co-primary outcome is to determine the feasibility of utilizing smartwatches among Exercise is Medicine participants aged 65+ as assessed by the number of eligible referrals agreeing to participate in the intervention, program attendance, and completion rates. | 12 months | |
Primary | Acceptability of EIM+ | The co-primary outcome is to determine the acceptability of utilizing smartwatches among Exercise is Medicine (EIM) participants aged 65+ as assessed by survey responses on perception of wearable devices integrated in to the EIM program and program attendance and completion rates. | 12 months | |
Secondary | Change in physical activity | The secondary outcome of physical activity levels before, during and after program completion (preliminary efficacy) will be examined both continuously (moderate-vigorous physical activity minutes per week) and categorically (meeting the goal of 150 minutes of moderate-vigorous physical activity per week). | 12 months | |
Secondary | Change in weight | The secondary outcome is weight before, during and after program completion | 12 months | |
Secondary | Change in BMI | The secondary outcome is BMI before, during and after program completion | 12 months | |
Secondary | Change in hip circumference | The secondary outcome is hip circumference before, during and after program completion | 12 months | |
Secondary | Change in waist circumference | The secondary outcome is waist circumference before, during and after program completion | 12 months | |
Secondary | Change in blood pressure | The secondary outcome is blood pressure before, during and after program completion | 12 months | |
Secondary | Change in heart rate variability | The secondary outcome is heart rate variability before, during and after program completion | 12 months | |
Secondary | Change in hemoglobin A1c | The secondary outcome is hemoglobin A1c before, during and after program completion | 12 months | |
Secondary | Change in perceived stress | The secondary outcome is perceived stress before, during and after program completion as assessed by responses to the Perceived Stress Scale assessment. | 12 months | |
Secondary | Change in depressive symptoms | The secondary outcome is depressive symptoms before, during and after program completion as assessed by responses to the Patient Health Questionnaire-9 (PHQ-9) | 12 months | |
Secondary | Change in diet | The secondary outcome is diet before, during and after program completion as assessed by responses to the Mediterranean Eating Pattern for Americans diet adherence screener. | 12 months | |
Secondary | Change in activity minutes per week | The secondary outcome is activity minutes per week before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in daily steps total | The secondary outcome is daily steps taken before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in measured steps per minute | The secondary outcome is measured steps per minute before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in sleep quality | The secondary outcome is sleep quality before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in sleep duration | The secondary outcome is sleep duration before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in estimated energy expenditure | The secondary outcome is estimated energy expenditure before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in heart rate | The secondary outcome is heart rate before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in distance moved | The secondary outcome is distance moved before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in minutes of vigorous activity | The secondary outcome is minutes of vigorous activity before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in minutes of moderate activity | The secondary outcome is minutes of moderate activity before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in minutes of light activity | The secondary outcome is minutes of light activity before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in minutes of sedentary time | The secondary outcome is minutes of sedentary time before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in number of manually entered and automatically detected physical activities (walking, running, etc.) | The secondary outcome is manually entered and automatically detected physical activities (walking, running, etc.) before, during and after program completion as assessed by smartwatch tracking. | 12 months | |
Secondary | Change in quality of life measures | The secondary outcome is quality of life measures before, during and after program completion as assessed by responses to the RAND Short Form (RAND-SF 36) v1.0 survey. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |